FIELD: biotechnology.
SUBSTANCE: options of a human antibody that immuno-specifically bind to human IL-5 are proposed. Nucleic acid, an expression vector, and a cell for expressing antibodies according to the invention are also proposed. Besides, the invention relates to the use of the specified antibodies and pharmaceutical compositions containing them for the treatment of eosinophilic asthma, hypereosinophilic syndrome, nasal polyposis with eosinophilic lesion, eosinophilic granulomatosis with polyangiitis, atopic dermatitis or eosinophilic esophagitis. Antibody molecules can bind to human IL-5 with an equilibrium affinity constant (KD) of at least about 40 pM that is determined by surface plasmon resonance.
EFFECT: obtaining anti-IL-5 antibodies.
20 cl, 24 dwg, 15 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| CD40 LIGAND THERAPEUTIC ANTIBODIES | 2018 |
|
RU2770209C2 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| ANTI-CLDN-18.2 ANTIBODY AND USE THEREOF | 2021 |
|
RU2829997C1 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2743464C2 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| ANTIBODIES DIRECTED AGAINST Fc-RECEPTOR-LIKE PROTEIN 5 AND METHODS FOR THEIR APPLICATION | 2016 |
|
RU2774158C2 |
| ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN, AND USE THEREOF | 2020 |
|
RU2825304C2 |
| FUSED PROTEIN CONSTRUCTS FOR COMPLEMENT-RELATED DISEASE | 2019 |
|
RU2824402C2 |
| CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND USE THEREOF | 2020 |
|
RU2819228C2 |
